Hep C Discussion Forum

The European Association for the Study of the Liver has issued new guidelines for the treatment of hepatitis C which recommend that wherever possible, patients should be treated with the newest direct-acting antivirals

EASL is also encouraging European physicians to combine products from different pharmaceutical companies to achieve the most potent interferon-free regimens, often in advance of full phase III trial data, in its new hepatitis C treatment guidelines issued on Friday at the International Liver Congress in London.

The guidelines move beyond US recommendations issued in January, which incorporated a small number of off-label uses not included in the US licenses for sofosbuvir and simeprevir. The new guidelines also include daclatasvir, a NS5A inhibitor that is likely to receive approval in Europe later this year.

Full details and recommendations...

http://www.aidsmap.com/European-liver-specialists-recommend-mix-and-match-approach-to-new-hepatitis-C-drugs/page/2846012/